Climb Bio Inc. Ordinary Shares CLYM 深 滬
等待開盤 09-11 09:30:00 美东时间
2.38
0.000
0.00%
華盛通- 最 高2.48
- 今 開2.33
- 成交量 24.16万股
- 最 低 2.33
- 昨 收 2.38
- 總市值 1.61亿
- 52周最高 8.58
- 市盈率 靜 --
- 換手率 0.36%
- 52周最低 1.05
- 委 比 5.46%
- 總股本 6757.58万
- 歷史最高 29.69
- 量 比 0.46
- 振 幅 6.30%
- 歷史最低 1.05
- 每 手 1
- 風險率 1.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
Climb Bio announces a webcast event on September 29, 2025, featuring its CLYM116 program, a novel anti-APRIL monoclonal antibody targeting IgA nephropathy. The event will include an overview of IgAN, preclinical data comparing CLYM116 to existing treatments, and the company's development strategy. CLYM116 employs a unique 'sweeper' mechanism, potentially offering best-in-class efficacy with less frequent dosing. The webcast will be accessible via...
09-04 11:00
Climb Bio to Present at Upcoming September 2025 Investor Conferences
Climb Bio, a clinical-stage biotechnology company, announced that its executives will participate in several upcoming investor conferences in New York and virtually. The events include the Cantor Global Healthcare Conference on September 5, the Baird Global Healthcare Conference on September 9, the Morgan Stanley Global Healthcare Conference on September 10, and the Stifel Virtual Immunology and Inflammation Forum on September 10. Live webcasts a...
08-25 11:00
Climb Bio GAAP EPS of -$0.13
Climb Bio press release (NASDAQ:CLYM): Q2 GAAP EPS of -$0.13. Cash, cash equivalents and marketable securities were $187.4 million as of June 30. Cash, cash equivalents and marketable securities are e...
08-12 23:51
Climb Bio Q2 EPS $(0.13) Beats $(0.17) Estimate
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 92.82 percent increase over losses of $(1.81) per share from the
08-12 19:10
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Climb Bio reported Q2 2025 financial results, highlighting progress with its lead product budoprutug in clinical trials for immune thrombocytopenia (ITP), systemic lupus erythematosus (SLE), and primary membranous nephropathy (pMN). The company also announced plans to initiate a Phase 2 trial for pMN and a Phase 1 trial for the subcutaneous formulation of budoprutug. CLYM116, targeting IgA nephropathy (IgAN), is advancing toward clinical developm...
08-12 11:00
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
Climb Bio appoints Dr. Edgar Charles as CMO and Cindy Driscoll as Senior Vice President, Finance. Dr. Charles brings over 20 years of experience in immunology-focused drug development, while Cindy has extensive financial leadership in biotech. Their expertise strengthens Climb Bio’s clinical programs for immune-mediated diseases, including budoprutug and CLYM116. Both executives received equity awards as part of their inducement packages.
06-18 11:00
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
Oppenheimer Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $10
Oppenheimer analyst Leland Gershell initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating and announces Price Target of $10.
06-07 01:10
Climb Bio GAAP EPS of -$0.31
Climb Bio press release (NASDAQ:CLYM): Q1 GAAP EPS of -$0.31. Cash Position: Cash, cash equivalents and marketable securities were $197.8 million as of March 31, 2025. Cash, cash equivalents and marke...
05-14 21:53
Climb Bio Q1 EPS $(0.31) Misses $(0.15) Estimate
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.15) by 106.67 percent. This is a 416.67 percent decrease over losses of $(0.06) per share from the
05-14 19:12
